View More View Less
  • 1 Szabolcs-Szatmár-Bereg megyei Jósa András Oktatókórház, 4400 Nyíregyháza, Lukács Ödön utca 4.
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $96.00

Absztrakt:

Az utóbbi bő egy évtizedben egyre több új fogalommal és jellegzetes, többnyire négy betűből álló rövidítéseikkel találkozunk a külföldi közleményekben, amelyek rövid áttekintése talán nem felesleges. Jelenlegi munkánkban a kérdéssel kapcsolatos legfontosabb ismereteket foglaljuk össze.

Bevezetésként felsoroljuk a szóban forgó rövidítéseket (és tömören megfogalmazott jelentésüket), majd ismertetjük ezeknek a fogalmaknak a lényegét, gyakorlati jelentőségét, klinikai vonatkozásait. Bár döntően hematológiai elváltozásokról lesz szó, ismeretük – mint később részletesebben is kifejtjük – egyéb szakterületek számára sem érdektelen. A genetikai vonatkozások részletes elemzése messze meghaladná célkitűzéseinket, ezért csupán a mondanivalónk szempontjából legfontosabbnak ítélt kérdéseket érintjük.

  • 1

    Wimazal F, Fonatsch C, Thalhammer R, et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: The diagnostic interface. Leuk Res. 2007; 31: 1461–1468.

  • 2

    Schroeder T, Ruf L, Bernhardt A, et al. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol. 2010; 21: 2267–2271.

  • 3

    Valent P, Bain BJ, Bennett JM, et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res. 2012; 36: 1–5.

  • 4

    Malcovati L, Cazzola M. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potencial (CHIP). Hematology Am Soc Hematol Educ Program 2015; 2015: 299–307.

  • 5

    Bejar R. CHIP, ICUS, CCUS and other four-letter words. Leukemia 2017; 31: 1869–1871.

  • 6

    Jan M, Ebert BL, Jaiswal S. Clonal hematopoiesis. Semin Hematol. 2017; 54: 43–50.

  • 7

    Gibson CJ, Steensma DP. New insights from studies of clonal hematopoiesis. Clin Cancer Res. 2018; 24: 4633–4642.

  • 8

    Steensma DP. Clinical consequences of clonal hematopoiesis of indeterminate potential. Blood Adv. 2018; 2: 3404–3410.

  • 9

    Steensma DP. Clinical implications of clonal hematopoiesis. Mayo Clin Proc. 2018; 93: 1122–1130.

  • 10

    DeZern AE, Malcovati L, Ebert BL. CHIP, CCUS, and other acronyms: definition, implications, and impact on practice. Am Soc Clin Oncol Educ Book 2019; 39: 400–410.

  • 11

    Li S. Age-related clonal hematopoiesis. Blood 2018; 131: 496–504.

  • 12

    Valent P, Kern W, Hoermann G, et al. Clonal hematopoiesis with oncogenic potential (CHOP): separation from CHIP and roads to AML. Int J Mol Sci. 2019; 20: 289–307.

  • 13

    Jakó J, Kiss A. Praeleukaemia. [A praeleukaemiáról.] Orvosképzés 1976; 51: 312–320. [Hungarian]

  • 14

    Chen S, Liu Y. p53 involvement in clonal hematopoiesis of indeterminate potencial. Curr Opin Hematol. 2019; 26: 235–240.

  • 15

    Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012; 44: 1179–1181.

  • 16

    Patel JL. The clinical and laboratory features of clonal hematopoiesis of indeterminate potencial. Adv Mol Pathol. 2018; 1: 37–42.

  • 17

    Karlsson S. Tipping clonal hematopoiesis into transformation. N Engl J Med. 2018; 397: 295–296.

  • 18

    Fujino T, Kitamura T. ASXL1 mutation in clonal hematopoiesis. Experiment Hematol. 2020; 83: 74–84.

  • 19

    Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371: 2488–2498.

  • 20

    McKerrell T, Park N, Moreno T, et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Reports 2015; 10: 1239–1245.

  • 21

    Heuser M, Thol F, Ganser A. Clonal hematopoiesis of indeterminate potential. A risk factor for hematologic neoplasms. Dtsch Arztebl Int. 2016; 113: 317–322.

  • 22

    Desai P, Mencia-Trinchant N, Savenkov O, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 2018; 24: 1015–1023.

  • 23

    Abelson S, Collord G, Ng SWK, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 2018; 559: 400–404.

  • 24

    Young AL, Tong RS, Birmann BM, et al. Clonal hematopoiesis and risk of acute myeloid leukemia. Haematologica 2019; 104: 2410–2417.

  • 25

    Jakó J, Szerafin L. Leukemia- and lymphoma-associated flow cytometric, cytogenetic, and molecular genetic aberrations in healthy individuals. [Leukaemia/lymphoma specifikus áramláscitometriai, citogenetikai és molekuláris genetikai eltérések egészségesekben.] Orv Hetil. 2012; 153: 531–540. [Hungarian]

  • 26

    Jakó J, Szerafin L. Current problems of monoclonal B-cell lymphocytosis (MBL). [A monoklonális B-sejtes lymphocytosis (MBL) aktuális kérdései.] Hemat Transzf. 2012; 45: 15–21. [Hungarian]

  • 27

    Olkhovskiy IA, Garber JG, Gorbenko AS, et al. JAK2V617F-positive clonal hematopoiesis of indeterminate potencial in pregnant women. Obstetr Gynec Reprod. 2019; 13: 204–210.

  • 28

    Kennedy JA, Medeiros JJF, Dobson SM, et al. Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms. Blood 2018; 132: 2201–2205.

  • 29

    Coombs CC, Zehir A, Devlin SM, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 2017; 21: 374–382.

  • 30

    King KY, Huang Y, Nakada D, et al. Environmental influences on clonal hematopoiesis. Exp Hematol. 2020; 83: 66–73.

  • 31

    Park SJ, Bejar R. Clonal hematopoiesis in cancer. Experiment Hematol. 2020; 83: 105–112.

  • 32

    Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017; 377: 117–121.

  • 33

    Keaney JF. CHIP-ping away at atherosclerosis. N Engl J Med. 2017; 377: 184–185.

  • 34

    Khetarpal SA, Qamar A, Bick AG, et al. Clonal hematopoiesis of indeterminate potential reshapes age-related CVD: JACC review topic of the week. J Am Coll Cardiol. 2019; 74: 578–586.

  • 35

    Dorsheimer L, Assmus B, Rasper T, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019; 4: 25–33.

  • 36

    Li F, Wu X, Zhou Q, et al. Clonal hematopoiesis of indeterminate potential (CHIP): a potential contributor to atherosclerotic cardio/cerebrovascular diseases? Genet Dis. 2018; 5: 75–76.

  • 37

    Pardali E, Dimmeler S, Zeiher AM, et al. Clonal hematopoiesis, aging, and cardiovascular diseases. Exp Hematol. 2020; 83: 95–104.

  • 38

    Amorós-Pérez M, Fuster JJ. Clonal hematopoiesis driven by somatic mutations: A new player in atherosclerotic cardiovascular disease. Atheroscler. 2020; 297: 120–126.

  • 39

    Egyed M. The possible role of clonal hematopoiesis of indeterminate potencial in hematologic neoplasms and cardiovascular diseases. [Klonális haematopoiesis lehetséges szerepe malignus hematológiai és kardiovaszkuláris betegségekben.] Magyar Hematológiai Táraság Kongresszusa, 2019. Kongresszusi Hírek 4. [Hungarian]

  • 40

    Shi M, Sun X, Bick A, et al. The association between clonal hematopoiesis of indeterminate potential and inflammatory biomarkers among chronic kidney disease patients. Circulation 2020; 141: AP456.